Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis

Lennox J Jeffers, Fuad Hasan, Maria De Medina, Rajender Reddy, Talley Parker, Marcelo Silva, Leonardo Mendez, Eugene R Schiff, Michael Manns, Michael Houghton, Qui Lim Choo, George Kuo

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Many cases of chronic hepatitis and cirrhosis cannot be attributed to a known cause and are collectively referred to as cryptogenic chronic liver disease. We have evaluated the role of the hepatitis C virus m the oathogenesis of this condition in a retrospective serum analysis for antibody to hepatitis C virus in 129 patients with cryptogenic liver disease. Other causes of chronic hepatitis and cirrhosis were ruled out by clinical, serum biochemical and serological techniques. All 129 patients were HBsAg negative, but 28 (22%) had antibody to HBcAg. Sera were tested by radioimmunoassays using recombinant peptides for antibodies to nonstructural (C100-3 and C33c) and structural regions (C22) of HCV. Among the 129 patients, 61 (47%) had antibody to C100-3, 76 (59%) had antibody to C33c and 74 (57%) had antibody to C22. Seventy-nine (61%) were reactive with at least one and 76 (59%) were reactive with at least two HCV peptides (this is the criterion used for hepatitis C virus antibody reactivity). A proportion of patients with chronic hepatitis and cirrhosis (55 of 91; 60%) similar to that of patients without cirrhosis (21 of 38; 55%) had hepatitis C virus antibody. No significant clinical, serum biochemical or histological differences were noted between the group of patients with hepatitis C virus antibody and those without this antibody reactivity. Thus more than half the patients with cryptogenic chronic liver disease had hepatitis C virus antibody, suggesting that chronic HCV infection plays a major role in the origin of cryptogenic chronic hepatitis and cirrhosis.

Original languageEnglish
Pages (from-to)187-190
Number of pages4
JournalHepatology
Volume15
Issue number2
StatePublished - Feb 1 1992

Fingerprint

Hepatitis C Antibodies
Chronic Hepatitis
Fibrosis
Antibodies
Liver Diseases
Serum
Chronic Disease
Hepatitis B Core Antigens
Peptides
Hepatitis B Surface Antigens
Hepacivirus
Radioimmunoassay
Infection

ASJC Scopus subject areas

  • Hepatology

Cite this

Jeffers, L. J., Hasan, F., De Medina, M., Reddy, R., Parker, T., Silva, M., ... Kuo, G. (1992). Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis. Hepatology, 15(2), 187-190.

Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis. / Jeffers, Lennox J; Hasan, Fuad; De Medina, Maria; Reddy, Rajender; Parker, Talley; Silva, Marcelo; Mendez, Leonardo; Schiff, Eugene R; Manns, Michael; Houghton, Michael; Choo, Qui Lim; Kuo, George.

In: Hepatology, Vol. 15, No. 2, 01.02.1992, p. 187-190.

Research output: Contribution to journalArticle

Jeffers, LJ, Hasan, F, De Medina, M, Reddy, R, Parker, T, Silva, M, Mendez, L, Schiff, ER, Manns, M, Houghton, M, Choo, QL & Kuo, G 1992, 'Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis', Hepatology, vol. 15, no. 2, pp. 187-190.
Jeffers LJ, Hasan F, De Medina M, Reddy R, Parker T, Silva M et al. Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis. Hepatology. 1992 Feb 1;15(2):187-190.
Jeffers, Lennox J ; Hasan, Fuad ; De Medina, Maria ; Reddy, Rajender ; Parker, Talley ; Silva, Marcelo ; Mendez, Leonardo ; Schiff, Eugene R ; Manns, Michael ; Houghton, Michael ; Choo, Qui Lim ; Kuo, George. / Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis. In: Hepatology. 1992 ; Vol. 15, No. 2. pp. 187-190.
@article{895dadf3a613476c84df4b0177074573,
title = "Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis",
abstract = "Many cases of chronic hepatitis and cirrhosis cannot be attributed to a known cause and are collectively referred to as cryptogenic chronic liver disease. We have evaluated the role of the hepatitis C virus m the oathogenesis of this condition in a retrospective serum analysis for antibody to hepatitis C virus in 129 patients with cryptogenic liver disease. Other causes of chronic hepatitis and cirrhosis were ruled out by clinical, serum biochemical and serological techniques. All 129 patients were HBsAg negative, but 28 (22{\%}) had antibody to HBcAg. Sera were tested by radioimmunoassays using recombinant peptides for antibodies to nonstructural (C100-3 and C33c) and structural regions (C22) of HCV. Among the 129 patients, 61 (47{\%}) had antibody to C100-3, 76 (59{\%}) had antibody to C33c and 74 (57{\%}) had antibody to C22. Seventy-nine (61{\%}) were reactive with at least one and 76 (59{\%}) were reactive with at least two HCV peptides (this is the criterion used for hepatitis C virus antibody reactivity). A proportion of patients with chronic hepatitis and cirrhosis (55 of 91; 60{\%}) similar to that of patients without cirrhosis (21 of 38; 55{\%}) had hepatitis C virus antibody. No significant clinical, serum biochemical or histological differences were noted between the group of patients with hepatitis C virus antibody and those without this antibody reactivity. Thus more than half the patients with cryptogenic chronic liver disease had hepatitis C virus antibody, suggesting that chronic HCV infection plays a major role in the origin of cryptogenic chronic hepatitis and cirrhosis.",
author = "Jeffers, {Lennox J} and Fuad Hasan and {De Medina}, Maria and Rajender Reddy and Talley Parker and Marcelo Silva and Leonardo Mendez and Schiff, {Eugene R} and Michael Manns and Michael Houghton and Choo, {Qui Lim} and George Kuo",
year = "1992",
month = "2",
day = "1",
language = "English",
volume = "15",
pages = "187--190",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis

AU - Jeffers, Lennox J

AU - Hasan, Fuad

AU - De Medina, Maria

AU - Reddy, Rajender

AU - Parker, Talley

AU - Silva, Marcelo

AU - Mendez, Leonardo

AU - Schiff, Eugene R

AU - Manns, Michael

AU - Houghton, Michael

AU - Choo, Qui Lim

AU - Kuo, George

PY - 1992/2/1

Y1 - 1992/2/1

N2 - Many cases of chronic hepatitis and cirrhosis cannot be attributed to a known cause and are collectively referred to as cryptogenic chronic liver disease. We have evaluated the role of the hepatitis C virus m the oathogenesis of this condition in a retrospective serum analysis for antibody to hepatitis C virus in 129 patients with cryptogenic liver disease. Other causes of chronic hepatitis and cirrhosis were ruled out by clinical, serum biochemical and serological techniques. All 129 patients were HBsAg negative, but 28 (22%) had antibody to HBcAg. Sera were tested by radioimmunoassays using recombinant peptides for antibodies to nonstructural (C100-3 and C33c) and structural regions (C22) of HCV. Among the 129 patients, 61 (47%) had antibody to C100-3, 76 (59%) had antibody to C33c and 74 (57%) had antibody to C22. Seventy-nine (61%) were reactive with at least one and 76 (59%) were reactive with at least two HCV peptides (this is the criterion used for hepatitis C virus antibody reactivity). A proportion of patients with chronic hepatitis and cirrhosis (55 of 91; 60%) similar to that of patients without cirrhosis (21 of 38; 55%) had hepatitis C virus antibody. No significant clinical, serum biochemical or histological differences were noted between the group of patients with hepatitis C virus antibody and those without this antibody reactivity. Thus more than half the patients with cryptogenic chronic liver disease had hepatitis C virus antibody, suggesting that chronic HCV infection plays a major role in the origin of cryptogenic chronic hepatitis and cirrhosis.

AB - Many cases of chronic hepatitis and cirrhosis cannot be attributed to a known cause and are collectively referred to as cryptogenic chronic liver disease. We have evaluated the role of the hepatitis C virus m the oathogenesis of this condition in a retrospective serum analysis for antibody to hepatitis C virus in 129 patients with cryptogenic liver disease. Other causes of chronic hepatitis and cirrhosis were ruled out by clinical, serum biochemical and serological techniques. All 129 patients were HBsAg negative, but 28 (22%) had antibody to HBcAg. Sera were tested by radioimmunoassays using recombinant peptides for antibodies to nonstructural (C100-3 and C33c) and structural regions (C22) of HCV. Among the 129 patients, 61 (47%) had antibody to C100-3, 76 (59%) had antibody to C33c and 74 (57%) had antibody to C22. Seventy-nine (61%) were reactive with at least one and 76 (59%) were reactive with at least two HCV peptides (this is the criterion used for hepatitis C virus antibody reactivity). A proportion of patients with chronic hepatitis and cirrhosis (55 of 91; 60%) similar to that of patients without cirrhosis (21 of 38; 55%) had hepatitis C virus antibody. No significant clinical, serum biochemical or histological differences were noted between the group of patients with hepatitis C virus antibody and those without this antibody reactivity. Thus more than half the patients with cryptogenic chronic liver disease had hepatitis C virus antibody, suggesting that chronic HCV infection plays a major role in the origin of cryptogenic chronic hepatitis and cirrhosis.

UR - http://www.scopus.com/inward/record.url?scp=0026571061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026571061&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 187

EP - 190

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -